Cargando…
Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy
Peripheral neuropathy (PN) is one of the most common side effects of bortezomib therapy. The majority of bortezomib-related PN is a sensory neuropathy of mild to moderate degree, and is reversible after dose reduction or discontinuation. However, occasionally bortezomib-induced neuropathy can be sev...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514086/ https://www.ncbi.nlm.nih.gov/pubmed/23211009 http://dx.doi.org/10.1186/2162-3619-1-20 |
_version_ | 1782251961954861056 |
---|---|
author | Jeter, Ashley Kang, Yubin |
author_facet | Jeter, Ashley Kang, Yubin |
author_sort | Jeter, Ashley |
collection | PubMed |
description | Peripheral neuropathy (PN) is one of the most common side effects of bortezomib therapy. The majority of bortezomib-related PN is a sensory neuropathy of mild to moderate degree, and is reversible after dose reduction or discontinuation. However, occasionally bortezomib-induced neuropathy can be severe and affects motor and/or autonomic nerves, and may be mediated by immune process. The role of immune modulation therapy in the management of bortezomib-induced PN was not well established. Here, we reported a case of bortezomib-induced severe PN that responded well to plasma exchange and steroid treatment. |
format | Online Article Text |
id | pubmed-3514086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35140862012-12-05 Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy Jeter, Ashley Kang, Yubin Exp Hematol Oncol Letter to the Editor Peripheral neuropathy (PN) is one of the most common side effects of bortezomib therapy. The majority of bortezomib-related PN is a sensory neuropathy of mild to moderate degree, and is reversible after dose reduction or discontinuation. However, occasionally bortezomib-induced neuropathy can be severe and affects motor and/or autonomic nerves, and may be mediated by immune process. The role of immune modulation therapy in the management of bortezomib-induced PN was not well established. Here, we reported a case of bortezomib-induced severe PN that responded well to plasma exchange and steroid treatment. BioMed Central 2012-08-15 /pmc/articles/PMC3514086/ /pubmed/23211009 http://dx.doi.org/10.1186/2162-3619-1-20 Text en Copyright ©2012 Jeter and Kang; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Letter to the Editor Jeter, Ashley Kang, Yubin Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy |
title | Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy |
title_full | Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy |
title_fullStr | Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy |
title_full_unstemmed | Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy |
title_short | Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy |
title_sort | immune modulation therapy in the management of bortezomib-induced peripheral neuropathy |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514086/ https://www.ncbi.nlm.nih.gov/pubmed/23211009 http://dx.doi.org/10.1186/2162-3619-1-20 |
work_keys_str_mv | AT jeterashley immunemodulationtherapyinthemanagementofbortezomibinducedperipheralneuropathy AT kangyubin immunemodulationtherapyinthemanagementofbortezomibinducedperipheralneuropathy |